Mural Oncology Plc is a clinical-stage oncology company, which focuses on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its in-cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.
Follow-Up Questions
Qui est le CEO de Mural Oncology PLC ?
Dr. Caroline Loew est le President de Mural Oncology PLC, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action MURA ?
Le prix actuel de MURA est de $2.08, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Mural Oncology PLC ?
Mural Oncology PLC appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Mural Oncology PLC ?
La capitalisation boursière actuelle de Mural Oncology PLC est de $36.0M
Est-ce que Mural Oncology PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Mural Oncology PLC, y compris 2 achat fort, 4 achat, 3 maintien, 0 vente et 2 vente forte
